Table 2.
Rates of 6‐month recurrent venous thromboembolism, major bleeding, and mortality in both arms of CLOT, CATCH, Hokusai VTE Cancer, Select‐D, and Daltecan study
| Study | CLOT4 | CATCH33 | Hokusai VTE Cancer45 | Select‐D47 | Daltecan50 , a | ||||
|---|---|---|---|---|---|---|---|---|---|
| Arms | Warfarin | Dalteparin | Warfarin | Tinzaparin | Edoxaban | Dalteparin | Rivaroxaban | Dalteparin | Dalteparin |
| Recurrent VTE | 53/336 (15.8%) | 27/336 (8.0%) | 45/451 (10.5%) | 31/449 (6.9%) | 34/522 (6.5%) | 46/524 (8.8%) | 8/203 (3.9%) | 18/203 (8.9%) | 29/334 (8.7%) |
| Major bleeding | 12/335 (3.6%) | 19/338 (5.6%) | 11/451 (2.4%) | 12/449 (2.7%) | 29/522 (5.6%) | 17/524 (3.2%) | 11/203 (5.4%) | 6/203 (3%) | 26/334 (7.8%) |
| Mortality | 136/336 (40.5%) | 130/336 (38.7%) | 138/451 (30.6%) | 150/449 (33.4%) | 140/522 (26.8%) | 127/524 (24.2%) | 25%b | 30%b | 116/334 (33.8%) 12 months |
VTE, venous thromboembolism.
a
Daltecan study is a nonrandomized prospective cohort study.
b
The numbers of patients are not available.